A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Inclusion Criteria:

• Pregnant and an estimated gestational age (GA) (based on ultrasound dating) fromWeek 13^0/7 to Week 18^6/7 at randomization

• History of severe Hemolytic Disease of the Fetus and Newborn (HDFN) in a priorpregnancy defined as documented:

1. fetal anemia as result of HDFN or fetal hydrops as result of HDFN or receivedgreater than or equal to (>=)1 IUT as a result of HDFN or

2. fetal loss or neonatal death as a result of HDFN, with maternal alloantibodytiters for Rhesus antigen D protein (RhD), Kell, Kell Rhesus antigen C protein (Rhc), Rhesus antigen E protein (RhE), or RhC antigen above the critical levels (anti-Kell >=4; other >=16) and evidence of an antigen-positive fetus

• During the current pregnancy, presence of maternal alloantibody to RhD, Rhc, RhE, orRhC antigen with titers above the critical level (anti-Kell >= 4; other >=16) basedon the designated central lab results at screening

• Evidence of antigen-positivity corresponding to the current maternal alloantibody (RhD, Kell, Rhc, RhE, or RhC) confirmed by non-invasive antigen cell-free fetal DNA (cffDNA) performed at the central laboratory

• Have screening lab test results within values within the study protocol-specifiedparameters: a) albumin >= lower limit of normal (LLN); b) alanine transaminase (AST)less than or equal to (<=) 2 × upper limit of normal (ULN); c) alanine transaminase (ALT) <=2 × ULN d) creatinine <=0.8 milligrams per deciliter (mg/dL), SI: <=70.7micromole per liter (μmol/L), and Serum total immunoglobulins G (IgG) ≥ 600 mg/dLSI: >=6 g/L

• Medically stable on the basis of physical examination, medical history, vital signs, 12-lead ECG, and clinical lab tests performed at screening

Exclusion Criteria:

• Currently pregnant with a multiple gestation (twins or more)

• Evidence of fetal anemia prior to randomization in the current pregnancy

• History of severe preeclampsia prior to GA Week 34 or severe fetal growthrestriction (estimated fetal weight <3rd percentile, based on local fetal growthnormative standards) in a previous pregnancy

• Current uncontrolled hypertension

• History of myocardial infarction, unstable ischemic heart disease, or stroke

• Has any confirmed or suspected clinical immunodeficiency syndrome or has a familyhistory of congenital or hereditary immunodeficiency unless confirmed absent in theparticipant

• Has inflammatory or autoimmune diseases requiring immunosuppressive therapies thatmay jeopardize the safety of the participant

• Currently has a malignancy or has a history of malignancy within 3 years beforescreening (with the exception of localized basal cell carcinoma and/or squamous cellcarcinoma skin cancer that has been adequately treated with no evidence ofrecurrence for at least 3 months before the first study intervention administrationor cervical carcinoma in situ that has been treated with no evidence of recurrencefor at least 3 months before the first study intervention)

• Is currently receiving systemic corticosteroids or other immunosuppressants fordisorders unrelated to the pregnancy

• Has received or planning to receive plasmapheresis, immunoadsorption therapy,intravenous immunoglobulin (IV Ig), or any immunoglobulin (Ig)G fragmentcrystallizable (Fc)-related protein therapeutics during the current pregnancy

• Has a severe infection including opportunistic infections

• Presence of abnormal (protocol-specified) hematologic lab values during screening

• History of an unprovoked pulmonary embolism or history of recurrent deep veinthrombosis (DVT)

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.